Kilitch Drugs (India) Ltd Share Price

Pharmaceuticals

NSE: KILITCH Small Cap ISIN: INE729D01010

As on 13 June 2026 at 02:37 IST

₹183.64

+ 1.85

(1.02%)

Sell Buy

Over 1 Month

15.14%

Over 6 Months

6.42%

Over 1 Year

-18.34%

Over 3 Years

84.80%

Kilitch Drugs (India) Ltd Summary

Close ₹181.79

Open ₹180.67

High ₹189.50

Low ₹179.27

Volume 1,26,978

Net Turnover (in Cr) ₹2.34

52Wk High ₹250

52Wk Low ₹117.25

52Wk High / Low

117.25

250

Kilitch Drugs (India) Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹635.57

EPS (TTM) 9.27

Book Value (BV) 95.25

Div. Yield -

P/E (TTM) 19.53

Price/Book Value 1.90

Delivery % 32.87 %

Face Value 10

Key Ratios

PE Ratio 18.66

PB Ratio 2.30

EV to Sales 3.43

PEG Ratio 0.24

ROA 10.31

ROE 11.02

Debt-Equity 0.17

Net Profit Margin 14.44

Operating Profit Margin 21.10

Kilitch Drugs (India) Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	209.48	158.85	142.52	117.14	71.19
Total Expenses	175	139.50	130.50	107.53	66.07
Profit Before Tax	34.47	19.35	12.01	9.61	5.12
Profit After Tax	24.94	13.58	8.28	6.21	3.77
Operating Profit After Depreciation	39.52	25.28	16.93	10.81	5.87

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	64.41	61.98	64.22	64.54	29.96
Total Non Current Assets	138.87	94.07	93.12	95.74	122.81
Total Current Assets	173.92	145.99	126.40	114.10	80.36
Total Assets	312.78	240.06	219.52	209.85	203.18
Total Shareholder's Fund	202.33	176.29	151.60	139.09	127.13

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	17.54	-1.53	2.59	5.78	45.66
Net Cash Used In Investing Activities	-39.95	-8.16	7.92	-15.25	-37.57
Net Cash Used In Financing Activities	13.24	8.81	-0.72	7.03	1.61

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	195.30	137.79	122.38	109.72	74.21
Total Expenses	154.61	114.43	102.93	95.79	66.70
Profit Before Tax	40.69	23.35	19.45	13.93	7.51
Profit After Tax	31.16	17.57	15.72	10.53	6.16
Operating Profit After Depreciation	42.82	25.26	20.43	14.59	8.26

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	19.51	15.70	15.08	14.18	6.94
Total Non Current Assets	195.78	145.98	137.65	134.57	124.09
Total Current Assets	162.38	141.49	114.77	97.72	71.76
Total Assets	358.16	287.47	252.42	232.29	195.85
Total Shareholder's Fund	252.94	222.92	195.93	178.03	162.93

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	15.23	-2.58	6.10	5.21	6.13
Net Cash Used In Investing Activities	-41.42	-8.71	6.24	-16.08	-5.35
Net Cash Used In Financing Activities	15.65	11.40	3.04	7.55	2.27

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	89.60	53.81	48.92	43.14	61.23
Total Expenses	67.46	47.65	43.89	39.88	46.63
Profit Before Tax	20.21	5.60	9.39	3.45	13.85
Profit After Tax	14.88	4.32	8.04	2.26	10.22
Operating Profit after Depreciation	22.63	7.69	11.69	5.82	16.30

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	71.97	44.67	37.81	34.12	56.30
Total Expenses	52.50	38.95	34.14	30.55	42.40
Profit Before Tax	19.33	6.17	10.07	5.98	14.99
Profit After Tax	14	4.89	8.72	4.79	11.37
Operating Profit after Depreciation	20.61	7.33	11.28	7.07	16.22

Kilitch Drugs (India) Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 177.54

S2 173.29

S3 167.31

Pivot 183.52

R1 187.77

R2 193.75

R3 198

Moving Average

20 SMA 176.73

50 SMA 157

100 SMA 160.02

200 SMA 169.73

Kilitch Drugs (India) Ltd Corporate Actions

No available data

AGM Date: 29 Sep 2021

Kilitch Drugs India Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 23 2021 to September 29 2021 (both days inclusive) for the purpose of 29th Annual General Meeting (AGM) of the Company to be held on September 29 2021. This is to inform you that the 29th Annual General Meeting of the members of Kilitch Drugs (India) Limited was held today i.e. Wednesday, September 29, 2021, through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). In this regard, please find enclosed the proceedings as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As Per BSE announcement Dated on 29.09.2021) The Companys 29th Annual General Meeting (AGM) was held on Wednesday 29th September 2021 at 9:11 A.M through video conferencing or other audio visual means. In terms of the provisions of the Companies Act 2013 and the Rules made thereunder and as per the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Company had provided remote E-voting facility to its members. Mr. Deep Shukla Proprietor of M/s Deep Shukla and Associates Company Secretaries was appointed as the Scrutinizer to scrutinize the voting conducted through remote e-voting for the AGM. The Scrutinizers Report dated 30th September 2021 is attached as Annexure I. In terms of the provisions of Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the details of the results held through remote e-voting is attached herewith as Annexure II. (As Per BSE Announcement Dated on 9/30/2021 7:09:47 AM)

AGM Date: 29 Sep 2022

Board of Directors approved unaudited financial results for the quarter ended 30th June, 2022. approved the appointment of Cost Auditor. Approved Notice of 30th Annual General Meeting of the Company and fixed the date of the same. Dear Sir, Please find proceeding of 30th Annual General Meeting of the Companhy As per the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Company had provided remote e-voting and e-voting facility (during AGM) to its members on the business transacted at the 30th Annual General Meeting (AGM) of the Company held on Thursday, 29th September, 2022 at 10:00 A.M. through Video Conferencing (VC)/Other Audio Video Means (OAVM). The Company had appointed M/s. Deep Shukla & Associates, Practicing Company Secretary as the scrutinizer for the remote e-voting and e-voting facility at the AGM. As per the Scrutinizer's Report, all resolutions as set out in the Notice of 30th Annual General Meeting have been duly approved by the members of the Company. Please find attached voting results and the Scrutinizer's Report on voting held through e-voting at the 30th AGM of the Company. (As Per BSE Announcement dated on 30.09.2022)

AGM Date: 29 Sep 2023

Considered and approved financial results for the quarter ended 30th June, 2023 Detail disclosure of Book Closure for the purpose of AGM is hereby enclosed Intimation to Stock Exchanges regarding newspaper publication of AGM notice (As Per BSE Announcement Dated on 04/09/2023) Enclosing the proceeding of the AGM (As Per BSE Announcement dated on 29.09.2023)

AGM Date: 27 Sep 2024

Notice of 32' Annual General Meeting of the Company for the financial year ended 31 March, 2024 to be convened and held on Friday, 27' September, 2024 at 9:30 am through video conferencing and other audio visual means only. We are hereby submitting the Notice of 32nd Annual General Meeting of the Company to be held on 27th September, 2024 (As per BSE Announcement Dated on 02/09/2024) We hereby submit proceeding and outcome of 32nd Annual General meeting of the Company (As per BSE Announcement Dated on 27/09/2024)

AGM Date: 26 Sep 2025

AGM 26/09/2025 Notice of 33 Annual General Meeting of the Company for the financial year ended 31st March, 2025 to be convened and held on Friday, 26th September, 2025 at 9:30 am through video conferencing and other audio visual means only We are enclosing herewith the proceeding and outcome of 33rd Annual General Meeting of the Company. (As Per Bse Announcement dated on 26/09/2025) We are submitting the scrutinizer report (As per BSE Announcement dated on: 27.09.2025)

EGM Date: 19 Jan 2022

EGM 19/01/2022 PROCEEDINGS OF EXTRA-ORDINARY GENERAL MEETING (EGM) OF THE COMPANY HELD ON WEDNESDAY, JANUARY 19, 2022 THROUGH VC/OAVM. Dear Sir/ Ma'am, The Company's Extra Ordinary General Meeting (AGM) was held on Wednesday, 19th January 2022 at 01:00 P.M through video conferencing or other audio visual means. In terms of the provisions of the Companies Act, 2013 and the Rules made thereunder and as per the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company had provided remote E-voting facility to its members. Mr. Deep Shukla, Proprietor of M/s Deep Shukla and Associates, Company Secretaries was appointed as the Scrutinizer to scrutinize the voting conducted through remote e-voting for the EGM. The Scrutinizer's Report dated 19th January 2022, is attached as Annexure I. In terms of the provisions of Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the details of the results held through remote e-voting is attached herewith as Annexure II. Kindly take the above intimation on record. (As Per BSE Announcement Dated on 19.01.2022) Kilitch Drugs India Ltd has informed BSE regarding the details of Voting results of EGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here (As Per BSE Announcement Dated 20.01.2022)

EGM Date: 11 Apr 2023

Disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We would like to inform you that Extraordinary General Meeting (EGM) of the Company will be held on Tuesday, 11th April, 2023, at 9:00 am (IST) through Video Conferencing or Other Audio Visual Means. (As per BSE Announcement Dated on 18/03/2023) Pursuant to Regulation 30 and 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 ('Listing Regulations'), please find enclosed herewith the copy of Newspaper Publication published on Sunday, 19th March, 2023 in the Free Press Journal - English Edition and Nava Shakti - Marathi Edition pertaining to Notice of Extraordinary General Meeting and e-voting details. (As Per BSE Announcement dated on 20.03.2023) This is to inform you that the Extraordinary General Meeting of the members of Kilitch Drugs (India) Limited was held today i.e. Tuesday, the 11th day of April, 2023 at 9:00 am through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). In this regard, please find enclosed the proceedings as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As per BSE Announcement Dated on 11/04/2023) As per the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Company had provided remote e-voting and e-voting facility (during EGM) to its members on the business transacted at the Extraordinary General Meeting (EGM) of the Company held on Tuesday, 11th April, 2023 at 9:00 A.M. through Video Conferencing (VC)/Other Audio Video Means (OAVM). The Company had appointed M/s. Deep Shukla & Associates, Practicing Company Secretary as the scrutinizer for conducting the e-voting process. The Scrutinizers' Report and Voting Results is enclosed herewith. (As per BSE Announcement Dated on 12/04/2023)

EGM Date: 13 Mar 2026

Please find attached unaudited standalone and consolidated financial results for the year ended 31st December 2026 We are submitting herewith the notice of EGM to be held on 13th March, 2026 (As per BSE Announcement dated on: 16.02.2026) We hereby submit proceeding of EGM We are submitting herewith the Scrutinizer''s Report (As per BSE Announcement dated on: 13.03.2026)

Kilitch Drugs (India) Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,794.30	₹4,30,512.67
Divis Laboratories Ltd	₹6,651.25	₹1,76,569.79
Torrent Pharmaceuticals Ltd	₹4,570	₹1,54,669.57
Cipla Ltd	₹1,383	₹1,11,725.01
Zydus Lifesciences Ltd	₹1,105.65	₹1,11,254.26

Kilitch Drugs (India) Ltd Top Mutal Funds Invested

No data available

Kilitch Drugs (India) Ltd News

Kilitch Drugs (India) to conduct board meeting

On 15 May 2026

07 May 2026, 04:01 pm

Kilitch Drugs (India) schedules EGM

On 13 March 2026

14 Feb 2026, 03:25 pm

Kilitch Drugs (India) announces board meeting date

On 11 February 2026

05 Feb 2026, 02:30 pm

Kilitch Drugs (India) to conduct board meeting

On 13 November 2025

11 Nov 2025, 11:10 am

Kilitch Drugs (India) AGM scheduled

On 26 September 2025

02 Sep 2025, 02:39 pm

Kilitch Drugs (India) Ltd Stock Analysis

Annual revenue for Kilitch Drugs (India) Ltd increased by 41.74% to ₹195.30 crore in FY 2025 from ₹137.79 crore in FY 2024.
Annual Net Profit for Kilitch Drugs (India) Ltd increased by 77.29% to ₹31.16 crore in FY 2025 from ₹17.57 crore in FY 2024.
Promoter Shareholding in Kilitch Drugs (India) Ltd remains unchanged by 0.00% in the most recent quarter, from 63.77% in March 2026 to 63.77% in March 2026.
Kilitch Drugs (India) Ltd delivered a 1-year return of -18.34% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
Kilitch Drugs (India) Ltd share price moved up by 1.02% from its previous close of INR ₹181.79. The latest Kilitch Drugs (India) Ltd share price is INR ₹183.64.
Kilitch Drugs (India) Ltd share price today has been at a low of 181.92 and a high of 186.15. Over the past 52 weeks, the Kilitch Drugs (India) Ltd share price has seen a low of 117.25 and a high of 250.